Table 1.
Baseline characteristics of patients who developed MRONJ or not
| Characteristics | Patients with MRONJ (n = 34) | Patients without MRONJ (n = 340) | P value |
|---|---|---|---|
| Male sex, n (%) | 20 (58.8%) | 192 (56.5%) | 0.857 |
| Age (years), median (IQR) | 70 (65–77) | 68 (62–75) | 0.191 |
| Weight (kg), median (IQR) | 56.8 (50.6–62.6) | 54.3 (46.5–62.4) | 0.271 |
| Type of disease, n (%) | – | ||
| Lung cancer | 10 (29.4%) | 143 (42.3%) | |
| Breast cancer | 6 (17.7%) | 61 (18.1%) | |
| Multiple myeloma | 4 (11.8%) | 52 (15.4%) | |
| Prostate cancer | 12 (35.3%) | 42 (12.4%) | |
| Othersa | 2 (5.9%) | 40 (11.8%) | |
| Comorbid disease, n (%) | |||
| Hypertension | 16 (47.1%) | 140 (41.2%) | 0.585 |
| Diabetes | 3 (8.8%) | 67 (19.7%) | 0.165 |
| Tooth extraction before starting BMAs, n (%) | 18 (51.4%) | 75 (22.1%) | < 0.001 |
| Concomitant medication, n (%) | |||
| Oral bisphosphonate | 1 (2.9%) | 12 (3.5%) | 1.000 |
| Antiangiogenic agents b | 11 (32.4%) | 62 (18.2%) | 0.067 |
| Steroid | 22 (64.7%) | 181 (53.2%) | 0.212 |
| Treatment agents, n (%) | |||
| Denosumab | 27 (79.4%) | 188 (55.3%) | 0.006 |
| Zoledronic acid | 7 (20.6%) | 152 (44.7%) | |
| Number of treatment courses, median (IQR) | |||
| Denosumab | 15 (10–27) | 8 (3–19) | 0.034 |
| Zoledronic acid | 17 (16–23) | 6 (2–15) | 0.001 |
| Tooth extraction after starting BMAs, n (%) | 10 (28.6%) | 10 (2.9%) | < 0.001 |
For continuous values, data are presented as the median (interquartile range (IQR))
MRONJ, medication-related osteonecrosis of the jaw
aIncludes renal cell carcinoma (n = 2) in patients with MRONJ, renal cell carcinoma (n = 13), gastric cancer (n = 5), colorectal cancer (n = 5), bladder cancer (n = 5), pancreatic cancer (n = 4), hepatocellular cancer (n = 3), esophageal cancer (n = 2), pharyngeal cancer (n = 1), extra mammary Paget’s disease (n = 1), and cancer of unknown primary (n = 1) in patients without MRONJ
bIncludes axitinib, bevacizumab, everolimus, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, and temsirolimus